VanEck Biotech ETF (NASDAQ:BBH) Sees Large Drop in Short Interest

VanEck Biotech ETF (NASDAQ:BBH) saw a significant decrease in short interest during the month of April. As of April 15th, there was short interest totalling 2,500 shares, a decrease of 67.9% from the March 31st total of 7,800 shares. Based on an average daily volume of 7,200 shares, the short-interest ratio is currently 0.3 days.

VanEck Biotech ETF Stock Down 1.6 %

NASDAQ:BBH traded down $2.56 during mid-day trading on Thursday, reaching $154.77. 53,720 shares of the company were exchanged, compared to its average volume of 9,120. VanEck Biotech ETF has a 12 month low of $142.51 and a 12 month high of $171.04. The company has a fifty day moving average of $162.38 and a 200 day moving average of $159.79.

Institutional Trading of VanEck Biotech ETF

Several hedge funds have recently modified their holdings of BBH. Commonwealth Equity Services LLC increased its position in VanEck Biotech ETF by 1.8% in the third quarter. Commonwealth Equity Services LLC now owns 28,705 shares of the company’s stock worth $4,470,000 after purchasing an additional 495 shares during the period. Envestnet Asset Management Inc. raised its stake in shares of VanEck Biotech ETF by 2.9% during the third quarter. Envestnet Asset Management Inc. now owns 21,949 shares of the company’s stock worth $3,418,000 after buying an additional 609 shares during the last quarter. Raymond James Financial Services Advisors Inc. raised its stake in shares of VanEck Biotech ETF by 34.5% during the fourth quarter. Raymond James Financial Services Advisors Inc. now owns 19,129 shares of the company’s stock worth $3,162,000 after buying an additional 4,909 shares during the last quarter. Valley Wealth Managers Inc. acquired a new position in VanEck Biotech ETF in the third quarter valued at approximately $2,956,000. Finally, Focus Financial Network Inc. ADV bought a new position in VanEck Biotech ETF in the fourth quarter valued at approximately $2,328,000. 32.05% of the stock is owned by institutional investors.

VanEck Biotech ETF Company Profile

The BIOTECH HOLDING COMPANY DEPOSITARY RECEIPTS or HOLDRS TRUST was formed under the depositary trust agreement, among The Bank of New York, as trustee, Merrill Lynch, Pierce, Fenner & Smith Incorporated, other depositors and the owners of the Biotech HOLDRS. The trust currently holds shares of common stock or American depositary shares issued by a group of companies that were, at the time of the initial offering, generally considered to be involved in various segments of thebiotechnology industry.